Ernexa Therapeutics Inc. Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31)
Ernexa Therapeutics Inc. (ERNA) reported Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) of 24.00% for the 3-month period ending 2013-03-31, per its 10-Q filed 2013-05-13.
Discontinued › Income Statement › Other Income
us-gaap:EntityWideRevenueMajorCustomerPercentage · last filed 2013-05-13
- Ernexa Therapeutics Inc. entity-wide revenue, major customer, percentage (deprecated 2013-01-31) for the quarter ending 2013-03-31 was 24.00%, a 9.09% increase year-over-year.
- Ernexa Therapeutics Inc. entity-wide revenue, major customer, percentage (deprecated 2013-01-31) for the quarter ending 2012-09-30 was 22.00%, a 0.00% change year-over-year.
- Ernexa Therapeutics Inc. entity-wide revenue, major customer, percentage (deprecated 2013-01-31) for the quarter ending 2012-06-30 was 22.00%, a 4.76% increase year-over-year.
- Ernexa Therapeutics Inc. entity-wide revenue, major customer, percentage (deprecated 2013-01-31) for the quarter ending 2012-03-31 was 22.00%.
- Ernexa Therapeutics Inc. entity-wide revenue, major customer, percentage (deprecated 2013-01-31) for fiscal 2012 was 23.00%, a 9.52% increase from fiscal 2011.
- Ernexa Therapeutics Inc. entity-wide revenue, major customer, percentage (deprecated 2013-01-31) for fiscal 2011 was 21.00%.
| Period end | Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) 3 month | Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) 6 month | Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) 9 month | Entity-Wide Revenue, Major Customer, Percentage (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2013-03-31 | 24.00% 10-Q · filed 2013-05-13 | |||
| 2012-12-31 | 23.00% 10-K · filed 2013-03-29 | |||
| 2012-09-30 | 22.00% 10-Q · filed 2012-11-09 | 23.00% 10-Q · filed 2012-11-09 | ||
| 2012-06-30 | 22.00% 10-Q · filed 2012-08-14 | 23.00% 10-Q · filed 2012-08-14 | ||
| 2012-03-31 | 22.00% 10-Q · filed 2013-05-13 | |||
| 2011-12-31 | 21.00% 10-K · filed 2013-03-29 | |||
| 2011-09-30 | 22.00% 10-Q · filed 2012-11-09 | 21.00% 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | 21.00% 10-Q · filed 2012-08-14 | 21.00% 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |